

# Movement Disorders Enrollment Form



Fax Referral To: 1-877-232-5455  
Address: 500 Ala Moana Blvd., Bldg 1 Honolulu, HI 96813

Phone: 1-808-254-2727  
NCPDP: 1203417

## Six Simple Steps to Submitting a Referral

### 1 PATIENT INFORMATION (Complete or include demographic sheet)

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Gender: ☐ Male ☐ Female  
Address: \_\_\_\_\_ City, State, ZIP Code: \_\_\_\_\_  
Preferred Contact Methods: ☐ Phone (to primary # provided below) ☐ Text (to cell # provided below) ☐ Email (to email provided below)  
*Note: Carrier charges may apply. By providing the phone number(s) and email address above, you are consenting to receive automated calls, emails and/or text messages from CVS Specialty® about your prescription(s), account, and health care. Standard data rates apply. Message frequency varies. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.*  
Primary Phone: \_\_\_\_\_ Alternate Phone: \_\_\_\_\_  
Email: \_\_\_\_\_ Last Four of SSN: \_\_\_\_\_ Primary Language: \_\_\_\_\_  
Parent/Caregiver/Legal Guardian Name (Last, First): \_\_\_\_\_ Relationship to patient: \_\_\_\_\_

### 2 PRESCRIBER INFORMATION

Prescriber's Name: \_\_\_\_\_ State License #: \_\_\_\_\_  
NPI #: \_\_\_\_\_ DEA #: \_\_\_\_\_ Group or Hospital: \_\_\_\_\_  
Address: \_\_\_\_\_ City, State, ZIP Code: \_\_\_\_\_  
Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Contact Person: \_\_\_\_\_ Contact's Phone: \_\_\_\_\_

### 3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)

Is the Patient Insured? ☐ Yes ☐ No Is the Patient enrolled or eligible for Medicare/Medicaid? ☐ Yes ☐ No  
Policy Holder's Name: \_\_\_\_\_ Policy Holder's DOB: \_\_\_\_\_ Relationship to Patient: \_\_\_\_\_  
Medical Insurance: \_\_\_\_\_ Telephone: \_\_\_\_\_ Policy ID: \_\_\_\_\_ Group #: \_\_\_\_\_  
Prescription Insurance: \_\_\_\_\_ Prescription Plan Telephone: \_\_\_\_\_  
Policy ID: \_\_\_\_\_ Group #: \_\_\_\_\_ RX BIN #: \_\_\_\_\_ RX PCN #: \_\_\_\_\_  
☐ Check box if patient is enrolled in manufacturer copay assistance If yes, please provide ID# \_\_\_\_\_

### 4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: \_\_\_\_\_ Ship to: ☐ Patient ☐ Office ☐ Other: \_\_\_\_\_

#### Diagnosis (ICD-10):

- ☐ G24.01 Tardive Dyskinesia (TD)  
☐ G10 Huntington's Chorea (HD)  
☐ G72.3 Periodic Paralysis  
☐ Other Code: \_\_\_\_\_ Description: \_\_\_\_\_

#### Patient Clinical Information:

Allergies: \_\_\_\_\_ Height: \_\_\_\_\_ in/cm Weight: \_\_\_\_\_ lb/kg

### 5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
<input type="checkbox"/> Austedo (initial prescription)	<input type="checkbox"/> 6 mg <input type="checkbox"/> 9 mg <input type="checkbox"/> 12 mg	<input type="checkbox"/> Administer 6 mg by mouth twice a day. Increase dose by 6 mg per day every week as needed to control symptoms. Maximum daily dose not to exceed 48 mg/day.	Quantity: 30-day supply Refills: 0
<input type="checkbox"/> Austedo (maintenance prescription)	<input type="checkbox"/> 6 mg <input type="checkbox"/> 9 mg <input type="checkbox"/> 12 mg	<input type="checkbox"/> Administer 6 mg by mouth twice a day. Increase dose by 6 mg per day every week as needed to control symptoms. Maximum daily dose not to exceed 48 mg/day.	Quantity: _____ Refills: _____

### 6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute Prescriber's Signature: _____ Date: _____	May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature: _____ Date: _____
CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" _____ ATTN: New York and Iowa providers, please submit electronic prescription	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.

# Movement Disorders Enrollment Form

## Please Complete Patient and Prescriber information

Patient Name: \_\_\_\_\_ Patient DOB: \_\_\_\_\_ Patient Phone: \_\_\_\_\_  
Prescriber Name: \_\_\_\_\_ Prescriber Phone: \_\_\_\_\_

### 5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
<input type="checkbox"/> Austedo XR Initial Titration	Titration Kit ***	<input type="checkbox"/> Administer 12 mg by mouth once a day during Week 1, 18 mg by mouth once a day during Week 2, 24 mg by mouth once a day during Week 3, and 30 mg by mouth once a day during Week 4  *** Titration Kit contents: (Weeks 1 and 2 Blister Pack contains seven 12 mg tablets taken during Week 1; and contains seven 6 mg tablets and seven 12 mg tablets taken during Week 2. Weeks 3 and 4 Blister Pack contains seven 24 mg tablets taken during Week 3; and contains seven 6mg tablets and seven 24 mg tablets taken during Week 4.)	Quantity: 1 kit Refills: 0
<input type="checkbox"/> Austedo XR Maintenance	<input type="checkbox"/> 6 mg <input type="checkbox"/> 12 mg <input type="checkbox"/> 24 mg <input type="checkbox"/> 30 mg <input type="checkbox"/> 36 mg <input type="checkbox"/> 42 mg <input type="checkbox"/> 48 mg	Titrate weekly by 6 mg per day to reach the dose selected below: <input type="checkbox"/> Administer 24 mg by mouth once a day <input type="checkbox"/> Administer 30 mg by mouth once a day <input type="checkbox"/> Administer 36 mg by mouth once a day <input type="checkbox"/> Administer 42 mg by mouth once a day <input type="checkbox"/> Administer 48 mg by mouth once a day	Quantity: _____ Refills: _____
<input type="checkbox"/> Dichlorphenamide	<input type="checkbox"/> 50 mg	<input type="checkbox"/> Take ____ tablet(s) by mouth _____ daily. <input type="checkbox"/> Other _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Ingrezza (initial prescription)	<input type="checkbox"/> Initiation Pack *** <input type="checkbox"/> 40 mg <input type="checkbox"/> 60 mg <input type="checkbox"/> 80 mg	<input type="checkbox"/> Administer 40 mg by mouth once a day. After one week increase the dose by 20 mg every two weeks as needed to control symptoms. Maximum daily dose not to exceed 80 mg per day. <input type="checkbox"/> Other _____  *** Initiation Pack contents: 28-day blister pack contains 7 x 40 mg tablets and 21 x 80 mg tablets	Quantity: 30-day supply Refills: 0
<input type="checkbox"/> Ingrezza (maintenance prescription)	<input type="checkbox"/> 40 mg <input type="checkbox"/> 60 mg <input type="checkbox"/> 80 mg	<input type="checkbox"/> Administer 40 mg by mouth once a day <input type="checkbox"/> Administer 60 mg by mouth once a day <input type="checkbox"/> Administer 80 mg by mouth once a day <input type="checkbox"/> Other _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Ingrezza Sprinkle (initial prescription)	<input type="checkbox"/> 40 mg <input type="checkbox"/> 60 mg <input type="checkbox"/> 80 mg	<input type="checkbox"/> Administer 40 mg by mouth once a day. After one week increase the dose by 20 mg every two weeks as needed to control symptoms. Maximum daily dose not to exceed 80 mg per day. <input type="checkbox"/> Other _____	Quantity: 30-day supply Refills: 0
<input type="checkbox"/> Ingrezza Sprinkle (maintenance prescription)	<input type="checkbox"/> 40 mg <input type="checkbox"/> 60 mg <input type="checkbox"/> 80 mg	<input type="checkbox"/> Administer 40 mg by mouth once a day <input type="checkbox"/> Administer 60 mg by mouth once a day <input type="checkbox"/> Administer 80 mg by mouth once a day <input type="checkbox"/> Other _____	Quantity: _____ Refills: _____

☐ Patient is interested in patient support programs **STAMP SIGNATURE NOT ALLOWED** Ancillary supplies and kits provided as needed for administration

### 6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute <b>Prescriber's Signature:</b> _____ <b>Date:</b> _____	May Substitute / Product Selection Permitted / Substitution Permissible <b>Prescriber's Signature:</b> _____ <b>Date:</b> _____
<b>CA, MA, NC &amp; PR:</b> Interchange is mandated unless Prescriber writes the words "No Substitution" _____ <b>ATTN: New York and Iowa providers,</b> please submit electronic prescription	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

**CONFIDENTIALITY NOTICE:** This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.